Alzeca Bio is developing a platform technology to provide
a more accurate, lower cost diagnostic technology for
Alzheimer’...
Team
- Alzeca CEO and CoFounder
- Previous start-up/life
science, VC, I-Banking
experience

- Molecular
Oncologist
- VC ex...
LaunchPad Centr al
Ke y Par t ne r s

Ke y Activitie s

Valu e Pr o p o sit io n s

Cu st o m e r
Re lat io n sh ip s

Cu ...
What We Thought (Rx) : Failed
compounds can be reborn
What We Did
Informal Partners

Pharma
What We Learned: Just Because
You Can Does Not Mean You
should
What we Thought (Dx)
What We Did
Informal Partners

Pharma

Imaging
What We Learned
What’s Next
• Focus on Dx opportunities (tau in addition to
amyloid)
• Better understand reimbursement
Next Steps…
• Review our recent preclinical data with KOLs,
pharma, and imaging companies to determine
additional needs
• ...
Partnering/Customers Lay of the Lands (Populate this)
Pre-clinical research tool

Rodent PoC

Primate PoC

Phase 1 PoC

Ra...
Lessons Learned about Cost, Key Resources, and Activities
Hypothesis

Experiments

Results

Affordable to patients

Talk t...
What is best route to your destination?
Go out and talk to people!
It is about working your network
Every customer is unique
Attend Conferences
What do experts think?
Will people invest now?
product
Can you get there on your own?
Who is that strategic partner?
How do get to the deal?
Does your MVP work?
Is it going to be too expensive for the
patient?
Not only lower cost, Higher Resolution
Use it in pre-clinical testing first
That miracle drug!
Upcoming SlideShare
Loading in...5
×

Alzeca bio week 10

598

Published on

Published in: Education, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
598
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Alzeca bio week 10

  1. 1. Alzeca Bio is developing a platform technology to provide a more accurate, lower cost diagnostic technology for Alzheimer’s Disease. The platform is also being utilized to reformulate Alzheimer’s therapies in order to be more effective and less toxic. Week 9
  2. 2. Team - Alzeca CEO and CoFounder - Previous start-up/life science, VC, I-Banking experience - Molecular Oncologist - VC experience - MBA, Stanford - Internal Medicine - Health Services Researcher - UCSF Faculty - Senior development process engineer - Pharma Consultant - Mentor - R&D Consultant - Ph.D & Post-Doc, UCSF
  3. 3. LaunchPad Centr al Ke y Par t ne r s Ke y Activitie s Valu e Pr o p o sit io n s Cu st o m e r Re lat io n sh ip s Cu st o m e r Se g m e n ts  Ph a r m a ce u t ica l  Va lid a t e t h e  (D x) To o l t o e va lu a t e  In s t it u t io n s Co m p a n ie s d ia g n o s t ic t e ch n o lo g y e n d p o in t in clin ica l co n d u ct in g clin ica l in in vivo a n im a l t r ia ls t r ia ls  FD A  Co n t r a s t Ag e n t M a n u fa ct u r e r s  Im a g in g Eq u ip m e n t s t u d ie s a n d h u m a n  Sh o w h ig h  (D x) Accu r a t e ly  Ph a r m a ce u t ica l s e le ct in g p a t ie n t s fo r s t u d ie s . Co m p a n ie s clin ica l t r ia ls  Co n t r a s t Ag e n t r e s o lu t io n im a g in g a n d m a k e q u a n t it a t ive Ke y Re so u r ce s M a n u fa ct u r e r s  (D x) Pr o vid in g e a r ly d ia g n o s is t o s u s p e ct e d  Aca d e m ic la b s a n d p h a r m a co m p a n ie s t o r e fo r m u la t e AD t h e r a p ie s  CRO s M a n u fa ct u r e r s Ch an n e ls Alz h e im e r ' s p a t ie n t s  Ca p it a l  Exclu s ive r ig h t s t o in t e lle ct u a l p r o p e r t y a n d k n o w le d g e o f  (D x) Ea s ie r a cce s s  (D x) D ir e ct t o fo r p a t ie n t s pha rma groups r u n n in g clin ica l t r ia ls  H o s p it a ls  CRO s  (Rx) Pr o vid in g m o r e e ffe ct ive t h e r a p e u t ics  (Rx) Lice n s in g t o t o Alz h e im e r 's p a t ie n t s t r a d e s e cr e t s  Alz h e im e r ' s Pa t ie n t s p h a r m a g r o u p s fo r  R& D Pe r s o n n e l t h e r a p e u t ic  Re s e a r ch Fa cilit ie s r e fo r m u la t io n Co st St r u ct u r e  R& D /O p e r a t io n a l Pe r s o n n e l  In t e lle ct u a l Pr o p e r t y  Co n s u m a b le s (m a t e r ia ls t o m a k e p r o d u ct s )  Re s e a r ch An im a ls  Re s e a r ch Fa cilit ie s  M is ce lla n e o u s (Acco u n t in g , Tr a ve l, Co n fe r e n ce s ) Re ve n u e Str am x) Co n t r a s t Ag e n t e (D s  To o l fo r q u a n t it a t ive b io m a r k e r m e a s u r e m e n t t o m e a s u r e t h e r a p e u t ic e ffica cy  To o l fo r p a t ie n t s e le ct io n in clin ica l t r ia ls  Se llin g Th e r a p e u t ics t o Alz h e im e r ' s Pa t ie n t s  Se llin g d ia g n o s t ic a g e n t t o s u s p e ct e d Alz . p a t ie n t s  Lice n s in g d e live r y p la t fo r m t o p h a r m a co m p a n ie s d e ve lo p in g Alz . d r u g s Li c e n se d fr o m b u si n e ssm o d e l g e n e r a t i o n .c o m u n d e r a Cr e a t i ve Co m m o n s At t r i b u t i o n -S h a r e Al i ke 3 .0 Un p o r t e d Li c e n se
  4. 4. What We Thought (Rx) : Failed compounds can be reborn
  5. 5. What We Did Informal Partners Pharma
  6. 6. What We Learned: Just Because You Can Does Not Mean You should
  7. 7. What we Thought (Dx)
  8. 8. What We Did Informal Partners Pharma Imaging
  9. 9. What We Learned
  10. 10. What’s Next • Focus on Dx opportunities (tau in addition to amyloid) • Better understand reimbursement
  11. 11. Next Steps… • Review our recent preclinical data with KOLs, pharma, and imaging companies to determine additional needs • Elucidate inflection points for them to endorse, invest, and partner in early stage clinical studies • establish budget for each • Assess other AD diagnostics and treatments in development • Clarify and disseminate competitive advantages of ADx
  12. 12. Partnering/Customers Lay of the Lands (Populate this) Pre-clinical research tool Rodent PoC Primate PoC Phase 1 PoC Randomized phase 2 Randomized phase 3 Patient Stratification for clinical trials (Novel) Drug reformulation
  13. 13. Lessons Learned about Cost, Key Resources, and Activities Hypothesis Experiments Results Affordable to patients Talk to KOL, CMS consultants 1) ADx would be affordable and some patients would self pay. 2) CMS covers MRI w/o contrast agent. Key Capital, patents, R&D Resources personnel, facilities, development partners. Talk to pharma companies, KOL, patent lawyers 1) True. 2) CMS consultant. 3) FDA is a key partner/resource. Activities Talk to pharma companies, CROs, KOLs, Regulatory 1) True. 2) Each company has its own unique criteria. Cost Validate technology, prove safety in humans, regulatory pathway, demonstrate high resolution.
  14. 14. What is best route to your destination?
  15. 15. Go out and talk to people!
  16. 16. It is about working your network
  17. 17. Every customer is unique
  18. 18. Attend Conferences
  19. 19. What do experts think?
  20. 20. Will people invest now?
  21. 21. product
  22. 22. Can you get there on your own?
  23. 23. Who is that strategic partner?
  24. 24. How do get to the deal?
  25. 25. Does your MVP work?
  26. 26. Is it going to be too expensive for the patient?
  27. 27. Not only lower cost, Higher Resolution
  28. 28. Use it in pre-clinical testing first
  29. 29. That miracle drug!
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×